CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-20 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
== Structure == The 3D structure of human serum albumin has been determined by X-ray crystallography to a resolution of 2.5 ångströms (250 pm). Albumin is a 65–70kDa protein. Albumin comprises three homologous domains that assemble to form a heart-shaped protein. Each domain is a product of two subdomains that possess common structural motifs. The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chemistry. Structurally, the serum albumins are similar, each domain containing five or six internal disulfide bonds.
His method of testing won the Intel International Science and Engineering Fair Gordon E. Moore Award in the spring of 2012. The Boeing Company has patented the use of carbon nanotubes for structural health monitoring of composites used in aircraft structures. This technology is hoped to greatly reduce the risk of an in-flight failure caused by structural degradation of aircraft. Zyvex Technologies has also built a 54' maritime vessel, the Piranha Unmanned Surface Vessel, as a technology demonstrator for what is possible using CNT technology. CNTs help improve the structural performance of the vessel, resulting in a lightweight 8,000 lb boat that can carry a payload of 15,000 lb over a range of 2,500 miles. IMEC is using carbon nanotubes for pellicles in semiconductor lithography. In tissue engineering, carbon nanotubes have been used as scaffolding for bone growth. Carbon nanotubes can serve as additives to various structural materials. For instance, nanotubes form a tiny portion of the material(s) in some (primarily carbon fiber) baseball bats, golf clubs, car parts, or damascus steel. IBM expected carbon nanotube transistors to be used on Integrated Circuits by 2020.
=== Homoleptic complexes (only amino acid ligands) === Mixing simple metal salts with solutions of amino acids near neutral or elevated pH often affords bis- or tris complexes. For metal ions that prefer octahedral coordination, these complexes often adopt the stoichiometry M(aa)3 (aa = amino carboxylate, such as glycinate, H2NCH2CO2−). Complexes of the 3:1 stoichiometry have the formula [M(O2CC(R)HNH2)3]z. Such complexes adopt octahedral coordination geometry. These complexes can exist in facial and meridional isomers, both of which are chiral. The stereochemical possibilities increase when the amino acid ligands are not homochiral. Both the violet meridional and red-pink facial isomers of tris(glycinato)cobalt(III) have been characterized With L-alanine, L-leucine, and other amino acids, one obtains four stereoisomers. With cysteine, the amino acid binds through N and thiolate. Complexes with the 2:1 stoichiometry are illustrated by copper(II) glycinate [Cu(O2CC(R)HNH2)2], which akso exists as a pentacoordinate monohydrate. When the metal is square planar, these complexes can exist as cis and trans isomers. The stereochemical possibilities increase when the amino acid ligands are not homochiral. Homoleptic complexes are also known where the amino carboxylate is tridentate amino acids. One such complex is Ni(κ3-histidinate)2.
=== New rankings system === The UFC introduced official rankings in February 2013 using a weekly media voting panel. On June 20, 2026, the promotion began replacing that system with the Meta UFC Rankings, an Elo‑based mathematical model designed to prioritize objectivity through factors such as opponent quality, activity, and decay for long layoffs or outdated wins. The new framework removes pound‑for‑pound rankings and minimizes human involvement, with the media panel continuing only during a transition period.
Sources: en.wikipedia.org
Bioarchaeology has helped to dispel the idea that life for foragers of the past was "nasty, brutish and short"; bioarchaeological studies reported that foragers of the past were often healthy, while agricultural societies tended to have increased incidence of malnutrition and disease. One study compared foragers from Oakhurst to agriculturalists from K2 and Mapungubwe and reported that agriculturalists from K2 and Mapungubwe were not subject to the lower nutritional levels expected. Danforth argues that more "complex" state-level societies display greater health differences between elites and the rest of society, with elites having the advantage, and that this disparity increases as societies become more unequal. Some status differences in society do not necessarily mean radically different nutritional levels; Powell did not find evidence of great nutritional differences between elites and commoners, but did find lower rates of anemia among elites in Moundville. An area of increasing interest interested in understanding inequality is the study of violence. Researchers analyzing traumatic injuries on human remains have shown that social status and gender can have a significant impact on exposure to violence. Numerous researchers study violence in human remains, exploring violent behavior, including intimate partner violence, child abuse, institutional abuse, torture, warfare, human sacrifice, and structural violence.
=== Sexual dysfunction and suicidal thoughts associated with Propecia === In 2021, an investigation by Reuters revealed that Merck's baldness drug Propecia (finasteride) caused persistent sexual dysfunction in men. The drug has been linked to over 700 incidences of suicidal thoughts and 110 deaths. Merck has been receiving reports since 1998, but never included the risks on the label. In 2015, Merck was sued by consumer-rights law firm Hagens Berman over a wrongful death linked to Propecia.
=== Parkinson's disease === α-Synuclein is a protein that is associated with Parkinson's disease. In humans, this protein is encoded by the SNCA gene. α-Synuclein is involved in recycling synaptic vesicles that carry neurotransmitters and naturally occurs in an unfolded form. Elevated levels of α-Synuclein are found in patients with Parkinson's disease. There is a correlation between the concentration of unphosphorylated α-Synuclein present in the patient and the severity of Parkinson's disease. Specifically, phosphorylation of Ser129 in α-Synuclein has an impact on severity. Healthy patients have higher levels of unphosphorylated α-Synuclein than patients with Parkinson's disease. The measurement of change in the ratio of concentrations of phosphorylated α-Synuclein to unphosphorylated α-Synuclein within a patient could be a marker of the disease progression. Antibodies that target α-Synuclein at phosphorylated Ser129 are used to study the molecular aspects of synucleinopathies. Phosphorylation of Ser129 is associated with the aggregation of the protein and further damage to the nervous system. The aggregation of phosphorylated α-Synuclein can be enhanced if a presynaptic scaffold protein, Sept4, is present in insufficient quantities. Direct interaction of α-Synuclein with Sept4 inhibits the phosphorylation of Ser129. However, phosphorylation of Ser129 can be observed without synuclein aggregation in conditions of overexpression.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.